Transition Therapeutics to begin trial with Alzheimer's product AZD-103

By Elaine Rigoli

Tampa, Fla., April 27 - Transition Therapeutics, Inc. has received clearance from the Therapeutic Products Directorate of Health Canada to start a phase 1 clinical trial for AZD-103, a disease-modifying therapeutic candidate for the treatment of Alzheimer's disease.

This class of therapeutics provides significant advantages over the current products on the market that only treat disease symptoms, the company said in a news release.

"The initiation of a phase 1 clinical investigation of one of the most promising disease-modifying drug candidates, AZD-103, represents a major step forward for the company and offers a new hope for millions of Alzheimer's patients and their families seeking relief from this devastating disease," chairman and chief executive officer Tony Cruz said in the release.

The trial will evaluate the pharmacokinetics, safety and tolerability of escalating oral doses of AZD-103 in 12 healthy volunteers. Enrollment for the trial is expected to begin in May.

Toronto-based Transition is a product-focused biopharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.